Background: Evidence from experimental and epidemiologic studies suggests that vitamin B6 may reduce the risk of breast cancer.
Introduction
Identification of molecular mechanisms underlying breast carcinogenesis is fundamental to the prevention of breast cancer, the most common malignancy among women (1) . Although, many of the accepted breast cancer risk factors, such as age at menarche, parity, age at first full-term pregnancy, and age at menopause are difficult to modify, diet is a potentially modifiable factor. However, besides alcohol intake, no association of diet with postmenopausal breast cancer risk has been established (2) .
Pyridoxal 5 0 -phosphate (PLP), the active form of vitamin B6 (3), serves as a cofactor in more than 100 enzymatic reactions (4) . Vitamin B6 is involved in one-carbon metabolism, a sequence of biochemical processes that enrich the cellular supply of methyl groups for DNA synthesis, repair, and methylation (5) . Apart from its role as a coenzyme, vitamin B6 might affect carcinogenesis directly through inhibition of cell proliferation, oxidative stress, angiogenesis, and enhanced immune function (reviewed in ref. 6) .
Results from studies of the association of dietary vitamin B6 intake (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) or circulating PLP levels (18) (19) (20) with breast cancer risk are inconsistent. A randomized trial of combined folic acid, vitamin B6, and vitamin B12 reported significantly reduced breast cancer risk among women in the treatment arm of older (!65 years old) but not younger women (21) . We investigated prediagnostic plasma levels of PLP in relation to invasive breast cancer risk among postmenopausal women in the multiethnic cohort (MEC) study.
Materials and Methods

Study design and population
This case-control study was nested within the biospecimen subcohort of the MEC, a large prospective study of residents of Hawaii and Southern California, which included 118,441 women (22) . The populationbased sampling frames for the MEC included rolls from drivers' licenses, voters' registration, and the Health Care Financing Administration and was targeted to 5 ethnic groups: African-American, Hawaiian, Japanese, Latino, and whites. At cohort entry, participants completed a self-administered, 26-page baseline questionnaire that included queries on demographic characteristics, anthropometry, medical history, family history of cancer, reproductive and menstrual history, cancer risk factors, and detailed questions on diet. The MEC biospecimen subcohort was established from 1996 through 2006, with the majority of recruitment occurring after 2001. All surviving cohort members still residing in the catchment area were recontacted and asked to provide biologic specimens, including blood samples. Blood samples were drawn at a clinical laboratory or at the participants' homes and were kept refrigerated and protected from light until processed on average within 3 hours of collection. After centrifugation, blood components were aliquoted into 0.5-mL cryovials and stored in the vapor phase of liquid nitrogen (À150 C). A total of 36,458 female cohort members contributed to the biorepository from which the cases and controls were selected for the present study. Although, the participants in the biospecimen subcohort were slightly more educated (mean 13.6 years vs. 12.7 years), were more likely to be nonsmokers (13% vs. 17%), and had a family history of cancer (46% vs. 42%) than nonparticipants, they were similar in relation to other exposures and were generally representative of all cohort members.
The study protocol was approved by the Institutional Review Boards of the University of Hawaii and the University of Southern California, and all participants signed informed consent.
Case ascertainment and control selection
Linkages of the cohort to the Surveillance, Epidemiology, and End Results cancer registries in Hawaii and California are conducted annually to identify incident breast cancer cases diagnosed during the follow-up period. Linkages to state death files and the National Death Index are conducted to identify deaths. Postmenopausal women participating in the biospecimen repository, who were diagnosed with primary invasive breast carcinoma before the most recent tumor registry linkage (December 31, 2010) and provided blood sample before breast cancer diagnosis were included in this analysis. Breast cancer cases were identified using the International Classification of Diseases for Oncology, 3rd edition, (codes C50.0-C50.9). Controls were randomly selected from the pool of postmenopausal women who were alive and free of a breast cancer diagnosis and individually matched to cases in a 1:1 ratio on study site, ethnicity, date of birth (AE1 year), date of blood draw (AE6 months), time of blood draw (morning hours), hours fasting before blood draw (<6, 6 to <8, 8 to <10, !10), and use of menopausal hormones at blood draw (none; current use of estrogen, progesterone, or combination of both). A total of 706 postmenopausal breast cancer cases and 706 matched controls were available for analysis. Tumor estrogen receptor (ER) and progesterone receptor (PR) status was available for 617 (87%) and 597 (85%) of the cases, respectively.
Laboratory analyses
Plasma samples were analyzed in the Analytical Biochemistry laboratory of the University of Hawaii Cancer Center (A.A. Franke, director) by laboratory personnel blinded to the case-control status of the samples. The PLP assay was based on the method of Rybak and Pfeiffer (23) . Briefly, 150 mL freshly thawed plasma was mixed for 5 minutes with 10 mL aqueous 2 H 2 -pyridoxal-5 0 -phosphate (internal standard, donated by Stephen P. Coburn, Purdue University, Fort Wayne, IN) and 50 mL 10% aqueous metaphosphoric acid (Sigma). After shaking with 200 mL CH 2 Cl 2 , the supernatant aqueous layer was transferred into 350 mL round-bottom plates (MicroLiter Analytical Supplies) and 20 mL of the aqueous layer were injected into the liquid chromatography/ tandem mass spectrometry (LC/MS-MS) system (model Accela and TSQ-Ultra from Thermo Scientific Inc.). PLP was separated on an Ascentis Express C18 column (150 mm Â 3.0 mm; 2.7 mm; Supelco Inc.) and a 0.2 mm prefilter cartridge (2.1 mm i.d., ThermoFisher) at a flow rate of 0.6 mL/min with the following linear mobile phase gradient consisting of 5% aqueous acetic acid (A) and 0.1% formic acid in acetonitrile (B): %B ¼ 4% for 1 minute then to 95% in 2 minutes, held at 95% for 1 minute and changed to 4% in 0.1 minute followed by equilibration for 4 minutes. Quantitation was conducted by tandem mass spectrometry after positive electrospray ionization in selected reaction monitoring mode by scanning the transitions m/z 248.0 to 150.1 (at 18 eV) and m/z 229.9 (at 14 eV) for PLP and m/z 250.0 to 152.0 (at 18 eV) for deuterated PLP (internal standard). Instrument settings were as follows: spray voltage, 4,000 V; sheath gas, nitrogen; sheath gas pressure, 45 arbitrary units; ion transfer capillary temperature, 350 C. External calibration was conducted with aqueous solutions of authentic standards (Sigma) in the range 5 to 1,000 nmol/L, and stock concentrations were determined by absorbance readings (e ¼ 5,070 at 388 nm in water). On the basis of a total of 47 duplicate and 23 triplet samples, the intrabatch and interbatch coefficients of variation for PLP were 4.4% and 3.8%, respectively.
Statistical analysis
Statistical analysis was conducted using SAS 9.2. Conditional logistic regression models were used to calculate OR and 95% confidence intervals (CI) for the association of prediagnostic plasma PLP levels with postmenopausal breast cancer risk. Quartiles of the log-transformed PLP levels were based on the distribution among controls and entered into the models as indicator variables with the lowest quartile as a reference category. Trend was assessed on the basis of a variable assigned to the median of the appropriate quartile for the transformed variable. To identify potential confounders, covariates were tested individually and jointly and were included in the models if they produced a >10% change in regression coefficients for PLP or were associated with breast cancer risk or PLP levels among controls. All final models were uniformly adjusted for the following baseline variables: [body mass index (BMI) kg/m 2 ; continuous, log-transformed], education (continuous), family history of breast cancer among first-degree female relatives, age at menarche ( 12, 13-14, and !15 years), parity (0, 1, 2-3, and !4) and age at first live birth (nulliparous, 20, 21-25, and !26 years), years of contraceptive hormone use (none; <5, and !5years), age at natural menopause ( 50, 50-55, and >55 years), oophorectomy, hysterectomy, smoking status (never, past, and current), average ethanol consumption (g/d; continuous, log-transformed), and hours of daily moderate and vigorous physical activity (continuous, log-transformed). We also examined the inclusion of one-carbon compounds, such as folic acid, 5-methyltetrahydrofolate, methylmalonic acid (indicator for vitamin B12), cysteine, homocysteine, methionine, choline, and betaine, but none of them individually or jointly influenced the association of PLP with breast cancer risk. A sensitivity analysis to examine whether the association of PLP with breast cancer risk was influenced by the time between blood collection and diagnosis was conducted. A Wald test was used to assess heterogeneity across subtypes of cancer by hormone receptor status and time from blood collection to diagnosis ( 1 year and >1 year), using polytomous conditional logistic regression modeled via proportional hazards regression (24). Interactions between PLP and all covariates included in the models as well as other one-carbon compounds on the risk of postmenopausal breast cancer were examined using the Wald test of cross-product terms of PLP (as a trend variable) and each of the risk factors, in turn. All P values were 2-sided. P values <0.05 were considered statistically significant.
Results
The mean age of the study participants at blood draw was 67.9 years (SE: 0.3; range: 58-87 years; Table 1 ). All matching variables were similar between cases and controls. Cases and controls were also similar with respect to years of education, ages at menarche, first live birth, menopause, and hours of daily moderate or vigorous physical activity. Cases were more likely than were controls to have had a family history of breast cancer and to be overweight or obese. Cases also had lower parity than controls, reported higher daily alcohol consumption, and were more likely to be current tobacco smokers. Cases had lower mean prediagnostic PLP levels than did controls Plasma PLP levels were inversely associated with postmenopausal breast cancer risk (Table 2) . Women with PLP levels in the highest quartile had a 30% reduced risk of invasive breast cancer (95% CI: 0.50-0.98) as compared with the women with PLP levels in the lowest quartile (P trend ¼ 0.02). This association remained unchanged after excluding cases (and their matched controls) whose blood was collected within 1 year of their breast cancer diagnosis. In the analysis stratified by tumor hormone receptor status, strong inverse associations of plasma PLP levels with breast cancer risk among women with ER-positive, PR-positive, and ER-positive/PR-positive tumors were observed. No significant associations of PLP with postmenopausal breast cancer risk were observed among women diagnosed with hormone receptor negative tumors (P for heterogeneity ¼ 0.04 for the difference in breast cancer risk by hormone receptor status). No significant modification of the association of PLP levels with breast cancer risk was found by any of the covariates, including family history of breast cancer education, BMI, age at menarche, parity, age at first parturition, use of contraceptive and menopausal hormones, age at menopause, alcohol consumption, tobacco smoking and physical activity, age at blood collection, hours of fasting before blood collection, as well as other 1 one-carbon compounds (P > 0.16; data not shown), although there was some statistically significant (P ¼ 0.04) heterogeneity by ethnicity. Among Latino women, no association of PLP with breast cancer risk was observed ( Table 2) .
Discussion
In this large prospective study of postmenopausal women, prediagnostic plasma PLP levels were inversely associated with invasive breast cancer risk. This association was strongest in women with hormone-receptor positive tumors and remained unchanged in the analysis restricted to women whose blood was collected more than 1 year before cancer diagnosis. Inverse trends in the risk of postmenopausal breast cancer associated with higher PLP levels were generally consistent in all ethnic groups, with the exception of Latinas among whom PLP was (nonsignificantly) positively related to risk. We also found comparatively low PLP levels among Latina controls and a higher percentage of hormone-receptor negative tumors among Latina cases than among cases from other ethnicities. However, we were limited by our sample size to further explore these population subgroups.
Results from 3 other prospective studies of the association of circulating PLP levels with postmenopausal breast cancer risk have been reported (18) (19) (20) . In accordance with our findings, an inverse relation of PLP to postmenopausal breast cancer risk was observed in the NOTE: Cases and controls were matched on age of birth (AE1 year), study site (Hawaii or California), ethnicity, date of blood draw (AE6 months), hours fasting before blood draw (<6, 6 to <8, 8 to <10, !10), and use of menopausal hormones at blood draw (none; estrogen alone; progestin alone, combined estrogen and progestin). ), age at menarche, parity, age at first parity, use of contraceptive hormones (none, <5 years !5 years), oophorectomy, hysterectomy, age at natural menopause, current smoking status, ethanol consumption (continuous, g/d), hours of daily moderate/vigorous physical activity. b P for heterogeneity of PLP association with breast cancer risk by ethnicity, time between blood collection and diagnosis, and tumor hormone receptor status.
not found its association with breast cancer risk (7, (9) (10) (11) (12) (13) (14) (15) (16) . A significant reduction of breast cancer risk was found among older women (age !65 years), but not younger women, in the randomized trial of folic acid, vitamin B6, and vitamin B12 (21) . Although, it is not possible to distinguish the affects attributable to vitamin B6, folic acid, or vitamin B12.
Our finding of an inverse association of plasma PLP with the risk of hormone receptor positive breast cancer, but not ER-negative or PR-negative tumors, is novel as no heterogeneity was observed (P > 0.84) in the association of circulating PLP with breast cancer risk by hormone receptor status in the Women's Health Study (8) . The differential association of PLP with breast cancer risk by hormone receptor status may have biologic relevance as the etiology of these tumors is thought to be distinct (25) . Vitamin B6 is a coenzyme in one-carbon metabolism reactions, facilitating the transfer of methyl groups to tetrahydrofolate to yield 5,10-methylenetetrahydrofolate and the downstream generation of thymidylate and purine for DNA synthesis. Disruption of these reactions may create an imbalance in the generation of methyl groups required for DNA methylation and other biochemical processes. Altered DNA methylation has been observed in tumors at several sites (26) , and ER and PR expression in breast tumors has found to be associated with methylation of ER and PR gene cytosine-phosphate-guanine (CpG) islands (27, 28) .
Experimental studies suggest that supraphysiologic doses of vitamin B6 can reduce tumor cell growth in culture (29) (30) (31) (32) (33) (34) (35) (36) , including the growth of mammary tumor lines (34) (35) (36) . The exact mechanism through which vitamin B6 exerts antitumorigenic effects is presently unknown (6) . Decreased growth of tumor cells by vitamin B6 treatment has been attributed to modulation of steroid hormone receptor-mediated gene expression (34, (37) (38) (39) . Because steroid hormones are involved in the regulation of cellular growth, differentiation, and maintenance of physiologic function, the potential for PLP to modulate these hormones could represent a novel therapeutic approach to the inhibition of breast cancer growth. Besides its role in growth regulation, vitamin B6 possesses antiinflammatory properties that might reduce the risk of breast malignancy (40, 41) . In vitro studies indicate that vitamin B6 may act as an antioxidant (33, 42) ; thus, the suppressive effects of vitamin B6 on cellular proliferation might be mediated through reduced oxidative stress.
Major strengths of this study include its prospective design and the evaluation of prediagnostic levels of plasma PLP in a large sample of postmenopausal women and controls matched on several factors associated with breast cancer risk. A wide range of potential confounders of the PLP breast cancer association was available. Furthermore, the measurement of vitamin B6 was conducted by a sensitive tandem mass spectrometry-based method with low interassay variation. Our analysis was limited by a single measurement of PLP, which may not be representative of exposure during periods in a woman's life critical to breast cancer susceptibility and reduces the precision of the measurement. Although, the study sample was relatively large, statistical power to conduct subgroup analyses of hormone-negative tumors was modest.
This nested case-control study provides new evidence that circulating levels of vitamin B6 may be inversely related to the risk of invasive postmenopausal breast cancer. Although, the exact mechanism by which vitamin B6 may reduce the risk of breast cancer is presently unknown, laboratory data are overwhelming that this compound is critical to multiple pathways that might inhibit breast carcinogenesis. In conclusion, these results, in combination with information from 2 other prospective studies, suggest a role for vitamin B6 in the prevention of postmenopausal breast cancer.
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